Skip to content

CRISPR-AsCas12a with crRNA-Free Collateral Cleavage Activity for Electrochemical Diagnosis of HER2-Positive Breast Cancer.

Nov 2026 · ACS Sensors · 0 citations · 39 references
Medicine

Abstract

The CRISPR-Cas12a system has revolutionized molecular diagnostics; however, the strict requirement of crRNAs and target DNA for collateral cleavage activation restricts its flexibility in non-nucleic acid diagnostics. Herein, we demonstrate that AsCas12a exhibits an RNA-free collateral cleavage activity with the presence of manganese ions (Mn2+), which preferentially cleaves single-stranded DNA efficiently. Mechanistically, kinetic analyses reveal that AsCas12a exhibits a significantly higher binding affinity for Mn2+ than for magnesium ion (Mg2+), while molecular dynamics simulations suggest that Mn2+ coordination induces conformational changes to expose the RuvC endonuclease domain. Harnessing this unique property, an enzymatic cascade-amplified electrochemical biosensor integrating manganese nanoflowers is reported for the diagnosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. By equipping screen-printed gold electrodes with DNA reporters, this diagnostic tool enables high-precision HER2 quantification and successfully distinguishes various HER2-related cell lines. Furthermore, the biosensor has been extended to analyze HER2-positive exosomes, facilitating the dynamic tracking of serum exosome levels in tumor-bearing nude mice to evaluate therapeutic efficacy and accurately distinguish HER2-positive breast cancer patients in clinical samples. This RNA-free Cas12a system may provide new insights into CRISPR-based non-nucleic acid detection, emerging as a powerful tool for dynamic tumor monitoring and precision oncology.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.